Suramin

Suramin is a century-old polysulfonated naphthylurea drug with strong polyanionic binding properties 100 Years of Suramin. Developed by Bayer in the 1910s, it was one of the first synthetic antiparasitic agents and remains a treatment for early-stage human African trypanosomiasis caused by Trypanosoma brucei rhodesiense 100 Years of Suramin+1.

Beyond its antiparasitic role, suramin acts as a broad P2 purinergic receptor antagonist, meaning it blocks signaling by extracellular ATP. This activity, along with its ability to bind many other proteins, has prompted research into conditions like autism, viral infections, kidney disease, and neuroinflammation 100 Years of Suramin+3. However, the only approved human indication is sleeping sickness, and safety concerns limit wider use 100 years since the publication of the suramin formula.

In plain terms, suramin blocks signals carried by ATP, the energy currency of cells, which also acts as a danger signal outside cells. It does this by sticking to P2 receptors on cell surfaces, preventing ATP from binding Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial+2. This broad blockade dampens inflammation and cellular excitement driven by ATP Mechanisms of ligand recognition and channel opening for P2X2 receptors in lipid nanodiscs+1.

Suramin's large, negatively charged structure allows it to stick to many positively charged pockets on proteins, so it also inhibits viral entry, viral polymerases, cGAS, PI3K, and growth factor pathways 100 Years of Suramin+4. This polypharmacology makes it a powerful research tool but also increases off-target effects.

Because suramin is poorly absorbed orally and does not readily cross the blood-brain barrier, it is given by injection and primarily acts outside the brain 100 Years of Suramin+1.

Approved antiparasitic use: effective against early-stage T. b. rhodesiense sleeping sickness 100 Years of Suramin+1.

Autism: a small randomized trial showed low-dose suramin improved core symptoms versus placebo, but replication is needed Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial.

Antiviral activity: in cell studies, suramin blocks entry of SARS-CoV-2, chikungunya, and other viruses, with EC50 around 20 µM for COVID-19 Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions+3. In mice, it reduced chikungunya-induced joint disease Suramin treatment reduces chikungunya pathogenesis in mice.

Kidney disease: in animal models, suramin reduced inflammatory and fibrotic markers in chronic kidney disease and polycystic kidneys, but it also caused tubular injury in some settings Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency+2.

Osteoarthritis and disc degeneration: suramin preserved cartilage and reduced inflammatory markers in animal and cell models Suramin ameliorates osteoarthritis by acting on the Nrf2/HO-1 and NF-κB signaling pathways in chondrocytes and promoting M2 polarization in macrophages+2.

Neuroinflammation: in rodent models of Parkinson's and multiple sclerosis, suramin dampened neuroinflammation and improved motor function Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+1.

Research protocols for suramin almost always use intravenous administration because the molecule is not orally available 100 Years of Suramin+1. The only published human experimental dose for a non-infectious condition is 20 mg/kg IV once, used in the autism pilot trial Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Animal studies often employ 10–100 mg/kg by IV or intraperitoneal injection, given intermittently rather than daily due to suramin's long persistence Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+2.

Community-based research protocols typically space doses weeks apart. A common strategy starts with a low-dose exploratory phase (2.5–5 mg/kg every 1–2 weeks for 4–6 weeks) followed by a maintenance phase with longer intervals, always with close safety monitoring of kidney function and nerve health (community protocol). The interactive timeline above shows a representative schedule.

Suramin is not a peptide but a small molecule; it is highly water-soluble and stable in aqueous solution. In research settings, it is typically dissolved in sterile water or bacteriostatic water at concentrations of 5–10 mg/mL 100 Years of Suramin+1. Reconstitution is straightforward: add diluent slowly, swirl gently, and confirm clarity.

Storage: unreconstituted powder should be kept at 2–8°C or frozen for long-term storage. Reconstituted solution is best stored at 2–8°C and used within 14–28 days if sterility is maintained. Suramin hydrolyzes slowly at higher temperatures, so avoid prolonged room-temperature storage 100 Years of Suramin. Do not freeze-thaw repeatedly. For specific volume calculations, use the interactive calculator in this section.

Suramin's broad polyanionic binding means it can interact with many drugs and supplements. It may amplify the effects of other purinergic antagonists or inflammasome inhibitors (e.g., NLRP3 blockers) and could blunt the response to therapies that rely on ATP signaling 100 years since the publication of the suramin formula+1. Combining with nephrotoxic drugs like cisplatin presents uncertain risk: animal studies show suramin can both protect and harm kidneys depending on context Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle+1.

Suramin neutralizes extracellular histones and modulates endothelial signaling, so caution is advised with anticoagulants or antiplatelet agents Suramin treatment reduces chikungunya pathogenesis in mice. Because suramin can cause peripheral neuropathy, concurrent use with other neurotoxic medications (e.g., taxanes, platinum drugs) may increase risk 100 years since the publication of the suramin formula+1. Theoretical interactions exist with mitochondrial or immune-modulating supplements, but human data are lacking.

Suramin does not follow a typical daily cycling pattern because of its long tissue half-life. Research protocols almost always use intermittent dosing to avoid accumulation and toxicity 100 Years of Suramin+1. In community use, a common cycle is 4–8 weeks of dosing (e.g., every 1–2 weeks) followed by an equal or longer washout period, re-dosing only when the effect wanes and safety markers remain stable (community protocol).

The main drivers for cycling are risk of peripheral neuropathy and kidney injury, which can emerge after repeated exposure Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+1. Preclinical neuropathy is linked to calcium dysregulation in sensory neurons, and animal kidney studies show that suramin can cause tubular phospholipidosis even while improving inflammatory markers Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+1. Therefore, extended breaks between treatment blocks are strongly advised.

Suramin's broad activity means stacking with other compounds is highly experimental. Combining suramin with anti-inflammatory peptides like BPC-157 might have additive effects on tissue healing, but could also interfere with growth factor signaling (community protocol). In theory, stacking with mitochondrial support agents (e.g., SS-31, MOTS-c) could balance suramin's metabolic stress, but no direct evidence exists.

Suramin should not be stacked with other neurotoxic drugs or strong anticoagulants without careful monitoring. Introducing one new compound at a time with 1–2 weeks between additions is a prudent research practice to identify side effects. Always monitor renal function and nerve health in any combination protocol.

Suramin is approved as a prescription drug for the treatment of early-stage human African trypanosomiasis due to T. b. rhodesiense 100 Years of Suramin+1. However, current FDA marketing authorization in the United States is not confirmed by the available research corpus. The drug is not scheduled as a controlled substance in the U.S.

For sports, there is no evidence that suramin appears on the WADA Prohibited List, and its mechanisms are not typically considered performance-enhancing. Nevertheless, athlete use would likely require a therapeutic use exemption if administered, given its injectable prescription status.

Suramin has a significant adverse effect profile, especially at higher or prolonged doses. The most concerning risks are peripheral neuropathy (numbness, tingling, weakness) and kidney injury, including tubular damage Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+2. Preclinical studies show that a single high dose in mice caused sensory-motor deficits and axonal neuropathy, while in a PKD mouse model, suramin improved cyst growth but worsened kidney injury biomarkers Targeting P2X purinergic receptors with suramin alleviates rotenone-induced Parkinson's-like pathology via modulation of mitophagy and NLRP3-pyroptosis: Comparison with metformin+1.

Other recognized side effects include skin rash, gastrointestinal upset, fatigue, laboratory abnormalities, and a rare but serious ocular condition called vortex keratopathy 100 Years of Suramin+2. Due to these risks, baseline and regular monitoring of renal function, neurologic status, and vision is essential in any research protocol. Suramin should be avoided in individuals with pre-existing neuropathy, severe kidney disease, or active corneal issues.